Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244517 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL30595201 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL6998701 | 0.77 | — | — | |
| SCHEMBL2041524 | 0.74 | — | — | |
| SCHEMBL13320609 | 0.74 | — | — | |
| SCHEMBL11890308 | 0.71 | HRH4 (0.31) | — | |
| SCHEMBL4786039 | 0.71 | — | — | |
| SCHEMBL16215872 | 0.68 | GRIN1 (0.33) | — | |
| SCHEMBL22095647 | 0.67 | SIGMAR1 (0.42) | — | |
| SCHEMBL21166113 | 0.67 | GABRA1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431255-A | Pretreatment method of 3- (chloromethyl) -1-methyl-1H-1, 2, 4-triazole hydrochloride and compound preparation method | 武汉武药制药有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-115466227-B | Preparation method of 3- (chloromethyl) -1-methyl-1H-1, 2, 4-triazole hydrochloride | 杭州国瑞生物科技有限公司 | 2024-07-19 | — | — | CN | claimed |
| CN-115403534-B | Preparation method of 3- (chloromethyl) -1-methyl-1H-1, 2,4 triazole hydrochloride | 浙江科技学院 | 2023-12-26 | — | — | CN | claimed |
| CN-117186015-A | Preparation method of entecavir intermediate | 杭州励德生物科技有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-116041349-B | Xanthine compound, preparation method thereof and application thereof in preparation of novel coronavirus 3CL protease inhibitor | 吉斯凯(苏州)制药有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-116768807-A | Preparation method of 3- (chloromethyl) -1-methyl-1H-1, 2, 4-triazole hydrochloride | 浙江乐普药业股份有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-116041349-A | Xanthine compound, preparation method thereof and application thereof in preparation of novel coronavirus 3CL protease inhibitor | 吉斯凯(苏州)制药有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-115466227-A | Preparation method of 3- (chloromethyl) -1-methyl-1H-1,2,4-triazole hydrochloride | 杭州国瑞生物科技有限公司 | 2022-12-13 | — | — | CN | claimed |
| CN-115403534-A | Preparation method of 3- (chloromethyl) -1-methyl-1H-1,2,4 triazole hydrochloride | 浙江科技学院 | 2022-11-29 | — | — | CN | claimed |
| CN-115109004-A | Preparation method of 3- (chloromethyl) -1-methyl-1H-1, 2, 4-triazole hydrochloride | 汉瑞药业(荆门)有限公司 | 2022-09-27 | — | — | CN | claimed |
| CN-217466831-U | Titration detector for content of 3-chloromethyl-1-methyl-1H-1, 2, 4-triazole hydrochloride | 上海晋鲁医药科技有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-114751894-A | Preparation method of oral medicine for treating neocoronary pneumonia | 苏州立新制药有限公司 | 2022-07-15 | — | — | CN | claimed |
| US-20260125365-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2026-05-07 | — | — | US | disclosed |
| US-12559474-B2 | Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2026-02-24 | — | — | US | disclosed |
| CN-117186015-B | Enstevir intermediate Process for the preparation of intermediates | 杭州励德生物科技有限公司 | 2026-02-06 | — | — | CN | disclosed |
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-5985874-A | Substituted morpholine derivative and its use as a therapeutic agent | MERCK SHARP & DOHME LTD. (GB) | 1999-11-16 | — | — | US | disclosed |
| EP-0728752-A1 | Triazole compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-28 | — | — | EP | disclosed |
| US-5405861-A | Fungicides | TAKEDA CHEMICAL INDUSTRIES, CO., LTD. (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0421210-A2 | Triazole compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-04-10 | — | — | EP | disclosed |